Form 4: Aytu BioPharma CEO Joshua Disbrow Acquires 38,000 Employee Stock Options
SEC Form 4 Filing
CEO Joshua Disbrow reports acquisition of 38,000 employee stock options in Aytu BioPharma, Inc.
Summary
- On November 6, 2024, Joshua R. Disbrow, CEO of Aytu BioPharma, Inc., acquired 38,000 employee stock options.
- The exercise price of these options is $1.84.
- The options vest in installments, starting with 1/3 on November 6, 2025, and the remainder in 24 equal monthly installments beginning December 6, 2025.
- The options expire on November 6, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing simply reports the grant of stock options, which is a common practice. It doesn't inherently indicate positive or negative performance.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CEO may signal confidence to shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/06/2024 | Date of transaction: CEO Joshua Disbrow acquired 38,000 employee stock options. |
| 11/06/2025 | First vesting date for 1/3 of the options. |
| 12/06/2025 | Start date for remaining options vesting in 24 equal monthly installments. |
| 11/06/2034 | Expiration date of the options. |
| 11/08/2024 | Date of signature for the Form 4 filing. |
Keywords
Aytu BioPharma, Joshua Disbrow, stock options, Form 4, CEO, AYTU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.